DelveInsight Releases Report on IgA Nephropathy Drug Development

Market research firm DelveInsight has released its "IgA Nephropathy Pipeline Insight 2026" report, providing a global analysis of the drug development landscape for IgA Nephropathy (IgAN). The report focuses on data from approximately 25 companies and more than 30 drug candidates in various stages of development, encompassing both clinical and preclinical phases.

IgA Nephropathy, also known as Berger's disease, is a common kidney disorder that can lead to renal failure. The condition is characterized by the deposition of IgA immunoglobulins in the glomerular mesangium of the kidneys, triggering immune-mediated injury and potentially resulting in hematuria and proteinuria. While the exact cause remains multifaceted, it is understood to involve immune system dysregulation and genetic factors.

The report offers detailed information on the drugs in development, including their mechanisms of action, clinical studies, and development stages. The analysis also covers therapeutic types, routes of administration, and molecule types. Furthermore, the report identifies and assesses pipeline products that have been discontinued or are no longer progressing.

According to DelveInsight's analysis, the objective of IgAN drug development is to slow disease progression and preserve kidney function, as a definitive cure is not currently available. Supportive measures, such as blood pressure management and proteinuria-reducing medications, are crucial. The report, published in 2026, covers the global market with approximately 80 pages of analysis.